Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Expert Highlights Advances for Patients With PNH

July 25th 2017

Mohamed Kharfan-Dabaja, MD, discusses the future of PNH treatment, the various symptoms that can present in PNH, and the challenges that still remain for further improving outcomes.

Axicabtagene Ciloleucel Emerges as Potential Standard for Some NHL Patients

July 25th 2017

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Frontline Obinutuzumab Recommended for EU Approval for Follicular Lymphoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.

Midostaurin Recommended for EU Approval for AML

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of midostaurin to treat adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive.

Emerging Agents Poised to Transform AML Landscape

July 17th 2017

Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.

Expert Discusses State of CAR T-Cell Therapy in ALL

July 13th 2017

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL

July 12th 2017

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

ODAC Recommends Approval of Gemtuzumab Ozogamicin for Newly-Diagnosed AML

July 11th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.

TP53 Mutations Have Independent Prognostic Value in MCL

July 11th 2017

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

July 11th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

FDA Grants Dasatinib Priority Review for Children With Ph+ Chronic Phase CML

July 11th 2017

The FDA has accepted a supplemental new drug application for dasatinib (Sprycel) for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML).

Expert Discusses CD19 CAR T-Cell Therapy in B-Cell ALL

July 7th 2017

Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.

Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL

July 5th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

FDA Approves First Flow Cytometry-Based Diagnostic for Blood Cancer Detection

June 30th 2017

The FDA has approved ClearLLab multicolor reagents (T1, T2, B1, B2, M) for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.

Clinical Trials Exploring Novel Options for T-Cell Lymphoma

June 28th 2017

Jia Ruan, MD, PhD, discusses some of the ongoing work in the field of T-cell lymphoma and the unanswered questions investigators are still facing for these patients

Chemotherapy-Free Triplet Achieves 100% Response Rates in 3 Lymphoma Subtypes

June 27th 2017

The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.

Frontline Brentuximab Vedotin Extends PFS in Hodgkin Lymphoma

June 26th 2017

Frontline brentuximab vedotin (Adcetris) was associated with improved progression-free survival compared with standard chemotherapy in patients with advanced classical Hodgkin lymphoma, according to results from the phase III ECHELON-1 clinical trial.

Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin Lymphoma

June 25th 2017

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Polatuzumab Vedotin Demonstrates Durable Reponses in Follicular Lymphoma, DLBCL

June 25th 2017

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.